News

Under an exclusive global licensing agreement, Seattle Genetics will develop, fund, manufacture and commercialize Immunomedics’ solid tumor therapy candidate, IMMU-132. Seattle will also take the responsibility to start

The stay order passed by the US Court of Appeals for the Federal Circuit will allow both the firms to appeal against the ruling of a federal judge in a

The clinical study will be conducted across approximately 15 centers in the United States. Jazz Pharmaceuticals research and development global head and development and chief medical officer Karen

GSD Ia is a rare, orphan genetic disease that results in excess accumulation of glycogen and lipids in liver tissue.  Data to date showed that treatment with VK2809

With unique MistPro technology, Flonase Sensimist delivers a fine, gentle, yet powerful mist spray, providing non-drowsy, 24-hour relief of allergy symptoms including itchy, watery eyes, nasal congestion, runny

Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system. The drug’s effectiveness was demonstrated in a clinical study of 196

US-based Parsemus Foundation through a non-profit social venture subsidiary is developing the Vasalgel, which is injected into the duct that transports sperm from the testicle to the urethra. This,

Betrixaban is an oral, once-daily Factor Xa inhibitor anticoagulant. The NDA for betrixaban, an FDA Fast Track-designated therapy, is under priority review by the FDA for extended-duration prophylaxis

The US Food and Drug Administration (FDA) included the changes to the approved product labeling to reflect this important information for prescribers. Trulicity is available in a prefilled pen